<SEC-DOCUMENT>0001213900-24-100845.txt : 20250807
<SEC-HEADER>0001213900-24-100845.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20241121121407
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-24-100845
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jyong Biotech Ltd.
		CENTRAL INDEX KEY:			0001954488
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
		STREET 2:		XIZHI DIST.
		CITY:			NEW TAIPEI CITY
		STATE:			F5
		ZIP:			221
		BUSINESS PHONE:		(8862) 27325205

	MAIL ADDRESS:	
		STREET 1:		23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
		STREET 2:		XIZHI DIST.
		CITY:			NEW TAIPEI CITY
		STATE:			F5
		ZIP:			221
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Via EDGAR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn.:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ibolya Ignat</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Mary Mast</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Doris Stacey Gama</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Joe McCann</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Jyong Biotech Ltd.<BR>
    Response to the Staff&rsquo;s Comments on </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Statement on Form F-1/A </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Filed on November 1, 2024 (File No. 333-277725)</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sir and Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On behalf of our client, Jyong
Biotech Ltd., a Cayman Islands exempted company (the &ldquo;<B>Company</B>&rdquo;), we submit to the staff (the &ldquo;<B>Staff</B>&rdquo;)
of the Securities and Exchanges Commission (the &ldquo;<B>Commission</B>&rdquo;) this letter setting forth the Company&rsquo;s responses
to the comments contained in the Staff&rsquo;s letter dated November 15, 2024 on the Company&rsquo;s registration statement on Form F-1/A
filed on November 1, 2024 (the &ldquo;<B>Registration Statement</B>&rdquo;).&nbsp;Concurrently with the submission of this letter, the
Company is filing amendment No.7 to Registration Statement (the &ldquo;<B>Amendment No.7</B>&rdquo;) via EDGAR to the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Staff&rsquo;s comments
are repeated below in bold and are followed by the Company&rsquo;s responses. We have included page references in the Amendment No.7 where
the language addressing a particular comment appears. Capitalized terms used but not otherwise defined herein have the meanings set forth
in the Amendment No.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 132.6pt 0pt 7.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><U>Prospectus Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><U>Overview, page 1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.85pt 0pt 43.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">1.</TD><TD STYLE="text-align: justify">We note your response to prior comment 1. Please also update the language throughout
the filings where you cross reference your risk factor on page 31. As an example only, we note the references on pages 5, 7, 30, 112,
115, 124, 126, 128, 133, and 137.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.85pt 0pt 43.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><B>Response: In response to the
Staff&rsquo;s comments, the Company has revised the disclosure on page 5, 7, 30, 112, 115, 124, 126, 128, 129, 133, and 137 of the Amendment
No.7.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.85pt 0pt 43.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.85pt 0pt 43.1pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.85pt 0pt 43.1pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">2.</TD><TD STYLE="text-align: justify">In response to prior comment 2 you state that based on prior conversations with
the TFDA you anticipate that the TFDA will accord due consideration to the comments provided by the US FDA. We also note your disclosure
that you have not had discussion with the TFDA regarding the unavailability of API-1. Therefore, please include a brief discussion of
the prior conversations you have had with the TFDA that led you to such conclusion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.85pt 0pt 43.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><B>Response: In response to the
Staff&rsquo;s comments, the Company has revised the disclosure on page 2, 6, 115 and 137 of the Amendment No.7.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.85pt 0pt 43.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><U>Use of Proceeds, page 79</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 46.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">3.</TD><TD STYLE="text-align: justify">We note that in response to prior comment 8 you removed disclosure indicating your
plans to use $2.9 million of the proceeds for the settlement of the litigation with Taizhou Bay New District Administrative Committee
and commitments with Taizhou Resource Bureau and state that &ldquo;at this time&rdquo; Taizhou Resource Bureau has not claimed for the land
idling fee. We also continue to note that as of June 30, 2024 you had a net working capital deficit of approximately $11.7 million, which
included current liabilities of approximately $5 million and $3.1 million due to Taizhou Bay New District Administrative Committee and
commitments with Taizhou Resources Bureau. Therefore, we reissue the comment. Please clarify the source(s) of funds you intend to use
to settle the amounts owed. Please see Instruction 3 to Item 504 of Regulation S-K.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 46.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><B>Response: In response to the
Staff&rsquo;s comments, the Company has revised the disclosure on page 7 of the Amendment No.7.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 46.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><U>Research and Development Expenses,
page 92</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">4.</TD><TD STYLE="text-align: justify">In response to comment 9 you state that you have completed CMC documentation and
submitted it to the FDA on October 16, 2024. You also state here and on pages 95, 96, 120, and 128, that you received a denial notice
from the FDA stating that the FDA is unable to reach agreement on protocols designed to establish safety and efficacy until you can provide
complete CMC information of API-2 and a plan to establish comparability between API-1 and API-2. Please clarify whether you have also
submitted a plan to establish comparability between API-1 and API-2.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><B>Response: In response to the
Staff&rsquo;s comments, the Company has revised the disclosure on page 2, 4, 6, 31, 60, 92, 94, 96, 115, 120, 124, 128 and 137 of the
Amendment No.7.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><U>Our Drug Candidate MCS-2, page
120</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.</TD><TD STYLE="text-align: justify">We note your response to prior comment 6 and reissue. Please include a discussion
of the serious adverse event(s) reported that you were not able to conclude were unrelated to your product candidate(s). In this regard
we note that in response to our comment letter issued August 30, 2024, you included tables identifying serious adverse events for your
clinical trials for MCS-2-US and MCS-2-TWN and concluded that &ldquo;all of SAEs described above were &lsquo;not-related&rsquo; to MCS-2, except the
pancreatitis event in the MCS-2-US-c, where the pancreatitis occurred for only 3 days. The causality is &lsquo;possible related&rsquo; but not &lsquo;definitely
related&rsquo; because it was most likely a side effect of Metformin used to treat diabetes mellitus.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><B>Response: In response to the
Staff&rsquo;s comments, the Company has revised the disclosure on page 27 of the Amendment No.7.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 46.1pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><U>Legal Proceedings and Compliance
Taizhou Investment Dispute, page 145</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">6.</TD><TD STYLE="text-align: justify">In response to prior comment 11 you state that under PRC&rsquo;s civil procedure, before
the enforcement of an effective judgement form civil litigation is complete, the parties may choose to enter into a settlement agreement
and apply to the court to perform such agreement in lieu of enforcing the judgement. Please also state if there is a time frame in which
such settlement must be reached before the court enforces its judgement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><B>Response: In response to the
Staff&rsquo;s comments, the Company has revised the disclosure on page 38 and 145 of the Amendment No.7.</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If the Staff has any questions
or comments concerning the foregoing, or requires any further information, please contact Ross D. Carmel, Esq. at (212) 930-9700 ext.
645 or by email at rcarmel@srfc.law. Alternatively, please contact Shane Wu, Esq. at (202) 322-8852 or by email at swu@srfc.law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichenzia Ross Ference Carmel LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ross D. Carmel, Esq. &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ross D. Carmel, Esq. &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shane
Wu, Esq.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW
YORK, NY | 10036<BR>
T (212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ +T# 2(  A$! Q$!_\0
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M;N-=)M].UA3);WC*2F<@X)_,?E77:=\0X?$/C%-(T"T%_IR1%[K4E8A(C@X
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M59?MTC+-%9"8(N.A.>.YQ[UZ5IOPZD\.?$'^V- -O;://;>3<6>2"#CJO7N
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-P<Y+2Y-PHHHK(1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
